PURPOSE: Common variable immunodeficiency (CVID) comprises a heterogeneous group of primary immunodeficiency disorders. Immunophenotyping of memory B cells at the time of diagnosis is increasingly used for the classification of patients into subgroups with different clinical prognoses. The EUROclass classification is a widely used method. Levels of somatic hypermutation (SHM) have proven useful as a prognostic marker for recurrent respiratory tract infections. As time of presentation and diagnosis is highly variable in CVID patients, and diagnostic delay is a common problem, it is important to know whether classification parameters are stable over time. The purpose of the study was to address this question in a cohort of 33 CVID patients followed from 3 to 19 years after diagnosis (average follow-up 8.8 years). METHODS: Levels of class-switched memory B cells were analyzed using flow cytometric immunophenotyping, and patients were classified according to the EUROclass criteria. Affinity maturation of B cells was measured using Igκ-REHMA, which assesses somatic hypermutation in kappa light chain transcripts. Clinical manifestations in terms of splenomegaly, autoimmune disease and granulomatous disease were also determined. RESULTS: Switched memory B cells and levels of SHM were not consistently stable markers in a long-term follow-up setting. At a given time during follow-up, 60% of the patients were assigned to the EUROclass group SmB- (less than 2% switched memory B cells), but only 23% were consistently assigned to this group. Associations between clinical manifestations and levels of switched memory B cells or SHM were not observed in our study. CONCLUSION: Based on our findings, we suggest that immunologic characteristics in CVID patients should be evaluated several times after diagnosis using internationally standardized methods.
PURPOSE: Common variable immunodeficiency (CVID) comprises a heterogeneous group of primary immunodeficiency disorders. Immunophenotyping of memory B cells at the time of diagnosis is increasingly used for the classification of patients into subgroups with different clinical prognoses. The EUROclass classification is a widely used method. Levels of somatic hypermutation (SHM) have proven useful as a prognostic marker for recurrent respiratory tract infections. As time of presentation and diagnosis is highly variable in CVIDpatients, and diagnostic delay is a common problem, it is important to know whether classification parameters are stable over time. The purpose of the study was to address this question in a cohort of 33 CVIDpatients followed from 3 to 19 years after diagnosis (average follow-up 8.8 years). METHODS: Levels of class-switched memory B cells were analyzed using flow cytometric immunophenotyping, and patients were classified according to the EUROclass criteria. Affinity maturation of B cells was measured using Igκ-REHMA, which assesses somatic hypermutation in kappa light chain transcripts. Clinical manifestations in terms of splenomegaly, autoimmune disease and granulomatous disease were also determined. RESULTS: Switched memory B cells and levels of SHM were not consistently stable markers in a long-term follow-up setting. At a given time during follow-up, 60% of the patients were assigned to the EUROclass group SmB- (less than 2% switched memory B cells), but only 23% were consistently assigned to this group. Associations between clinical manifestations and levels of switched memory B cells or SHM were not observed in our study. CONCLUSION: Based on our findings, we suggest that immunologic characteristics in CVIDpatients should be evaluated several times after diagnosis using internationally standardized methods.
Authors: Antonello Giovannetti; Marina Pierdominici; Francesca Mazzetta; Marco Marziali; Cristina Renzi; Anna Maria Mileo; Marco De Felice; Barbara Mora; Antonella Esposito; Rossella Carello; Antonio Pizzuti; Marco G Paggi; Roberto Paganelli; Walter Malorni; Fernando Aiuti Journal: J Immunol Date: 2007-03-15 Impact factor: 5.422
Authors: Nima Rezaei; James B Wing; Asghar Aghamohammadi; Jennifer Carlring; Andrew Lees; Hossein Asgarian-Omran; Zahra Pourpak; Abdolfattah Sarrafnejad; Gholam A Kardar; Tahereh Shahrestani; Farimah Masoumi; Ahad Zare; Shiva Saghafi; Shokouh Sarrafzadeh; Rachel A Foster; Andrew W Heath; Robert C Read Journal: Hum Immunol Date: 2010-02-19 Impact factor: 2.850
Authors: Klaus Warnatz; Axel Denz; Ruth Dräger; Moritz Braun; Christoph Groth; Guido Wolff-Vorbeck; Hermann Eibel; Michael Schlesier; Hans Hartmut Peter Journal: Blood Date: 2002-03-01 Impact factor: 22.113
Authors: B Piqueras; C Lavenu-Bombled; L Galicier; F Bergeron-van der Cruyssen; L Mouthon; S Chevret; P Debré; C Schmitt; E Oksenhendler Journal: J Clin Immunol Date: 2003-09 Impact factor: 8.317
Authors: Krishna M Roskin; Noa Simchoni; Yi Liu; Ji-Yeun Lee; Katie Seo; Ramona A Hoh; Tho Pham; Joon H Park; David Furman; Cornelia L Dekker; Mark M Davis; Judith A James; Kari C Nadeau; Charlotte Cunningham-Rundles; Scott D Boyd Journal: Sci Transl Med Date: 2015-08-26 Impact factor: 17.956
Authors: Chantal E Hargreaves; Silvia Salatino; Sarah C Sasson; James E G Charlesworth; Elizabeth Bateman; Arzoo M Patel; Consuelo Anzilotti; John Broxholme; Julian C Knight; Smita Y Patel Journal: J Clin Immunol Date: 2021-05-19 Impact factor: 8.317